PURPOSE OF REVIEW: Severe pneumonia is a common disease that intensive care physicians have to face. The review highlights recent findings about microbiology, diagnosis and treatment, including the management of critically ill patients with severe respiratory failure. RECENT FINDINGS: Epidemiological and clinical risk factors strongly influence microbiological cause in patients with severe pneumonia. In addition to typical respiratory pathogens, less common microrganisms and multidrug-resistant (MDR) germs may cause severe lung infections. New molecular diagnostic techniques appear promising for early detection of microbes involved in severe pneumonia. Antimicrobials remain the mainstay of causative severe pneumonia treatment and the optimization of antibiotic therapy may be obtained by applying their pharmacodynamic/pharmacokinetic properties. Several new strategies have been implemented for the management of acute respiratory failure (ARF) due to severe pneumonia; however, their extensive clinical application is limited by the need for well trained physicians and adequate hospital centers. SUMMARY: Despite advancements in antibiotic and life-supportive treatments, severe pneumonia remains a leading cause of intensive care unit (ICU) admission and death. Prompt and appropriate antimicrobial therapy is essential. The use of new nonconventional strategies for ARF management might be effective in more severe patients.
PURPOSE OF REVIEW: Severe pneumonia is a common disease that intensive care physicians have to face. The review highlights recent findings about microbiology, diagnosis and treatment, including the management of critically illpatients with severe respiratory failure. RECENT FINDINGS: Epidemiological and clinical risk factors strongly influence microbiological cause in patients with severe pneumonia. In addition to typical respiratory pathogens, less common microrganisms and multidrug-resistant (MDR) germs may cause severe lung infections. New molecular diagnostic techniques appear promising for early detection of microbes involved in severe pneumonia. Antimicrobials remain the mainstay of causative severe pneumonia treatment and the optimization of antibiotic therapy may be obtained by applying their pharmacodynamic/pharmacokinetic properties. Several new strategies have been implemented for the management of acute respiratory failure (ARF) due to severe pneumonia; however, their extensive clinical application is limited by the need for well trained physicians and adequate hospital centers. SUMMARY: Despite advancements in antibiotic and life-supportive treatments, severe pneumonia remains a leading cause of intensive care unit (ICU) admission and death. Prompt and appropriate antimicrobial therapy is essential. The use of new nonconventional strategies for ARF management might be effective in more severe patients.
Authors: Gennaro De Pascale; Serena Fortuna; Mario Tumbarello; Salvatore Lucio Cutuli; MariaSole Vallecoccia; Teresa Spanu; Giuseppe Bello; Luca Montini; Mariano Alberto Pennisi; Pierluigi Navarra; Massimo Antonelli Journal: Intensive Care Med Date: 2014-11-21 Impact factor: 17.440
Authors: Yewande E Odeyemi; Svetlana Herasevich; Sarah J Chalmers; Erin F Barreto; Ryan D Frank; Ognjen O Gajic; Hemang Yadav Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2020-12-10
Authors: Gennaro De Pascale; Otavio T Ranzani; Saad Nseir; Jean Chastre; Tobias Welte; Massimo Antonelli; Paolo Navalesi; Eugenio Garofalo; Andrea Bruni; Luis Miguel Coelho; Szymon Skoczynski; Federico Longhini; Fabio Silvio Taccone; David Grimaldi; Helmut J F Salzer; Christoph Lange; Filipe Froes; Antoni Artigas; Emili Díaz; Jordi Vallés; Alejandro Rodríguez; Mauro Panigada; Vittoria Comellini; Luca Fasano; Paolo M Soave; Giorgia Spinazzola; Charles-Edouard Luyt; Francisco Alvarez-Lerma; Judith Marin; Joan Ramon Masclans; Davide Chiumello; Angelo Pezzi; Marcus Schultz; Hafiz Mohamed; Menno Van Der Eerden; Roger A S Hoek; D A M P J Gommers; Marta Di Pasquale; Rok Civljak; Marko Kutleša; Matteo Bassetti; George Dimopoulos; Stefano Nava; Fernando Rios; Fernando G Zampieri; Pedro Povoa; Lieuwe D Bos; Stefano Aliberti; Antoni Torres; Ignacio Martín-Loeches Journal: ERJ Open Res Date: 2017-11-17
Authors: Aaron D Storms; Jufu Chen; Lisa A Jackson; James D Nordin; Allison L Naleway; Jason M Glanz; Steven J Jacobsen; Eric S Weintraub; Nicola P Klein; Paul M Gargiullo; Alicia M Fry Journal: BMC Pulm Med Date: 2017-12-16 Impact factor: 3.317
Authors: Ahmed E Abou Warda; Rania M Sarhan; Hussein Saeed Al-Fishawy; Ayman N Moharram; Heba F Salem Journal: Pharmaceuticals (Basel) Date: 2022-02-28